(wherein R
1
and R
4
are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R
5
represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R
2
represents —C(═W)R
6
or the like; R
3
represents a hydrogen atom, —C(═W
A
)R
6A
, or the like)
Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.
(wherein R
1
and R
4
are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R
5
represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R
2
represents —C(═W)R
6
or the like; R
3
represents a hydrogen atom, —C(═W
A
)R
6A
, or the like)
Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.
A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient:
[wherein R
1
represents a hydrogen atom and the like, R
2
represents a hydrogen atom, —C(═W)R
6
(wherein W represents an oxygen atom or a sulfur atom, and R
6
represents substituted or unsubstituted lower alkyl and the like) and the like, R
3
represents —C(═Z)R
19
(wherein Z represents an oxygen atom or a sulfur atom, and R
19
represents substituted or unsubstituted lower alkyl and the like) and the like, R
4
represents substituted or unsubstituted lower alkyl and the like, and R
5
represents substituted or unsubstituted aryl and the like] and the like are provided.
A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient:
[wherein R
1
represents a hydrogen atom and the like, R
2
represents a hydrogen atom, —C(═W)R
6
(wherein W represents an oxygen atom or a sulfur atom, and R
6
represents substituted or unsubstituted lower alkyl and the like) and the like, R
3
represents —C(═Z)R
19
(wherein Z represents an oxygen atom or a sulfur atom, and R
19
represents substituted or unsubstituted lower alkyl and the like) and the like, R
4
represents substituted or unsubstituted lower alkyl and the like, and R
5
represents substituted or unsubstituted aryl and the like] and the like are provided.
A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient:
[wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, -C(=W)R6 (wherein W represents an oxygen atom or a sulfur atom, and R6 represents substituted or unsubstituted lower alkyl and the like) and the like, R3 represents -C(=Z)R19 (wherein Z represents an oxygen atom or a sulfur atom, and R19 represents substituted or unsubstituted lower alkyl and the like) and the like, R4 represents substituted or unsubstituted lower alkyl and the like, and R5 represents substituted or unsubstituted aryl and the like] and the like are provided.
一种有丝分裂驱动蛋白 Eg5 抑制剂,其活性成分包括通式 (I) 所代表的噻二唑 啉衍生物或其药理学上可接受的盐:
[其中 R1 代表氢原子等,R2 代表氢原子、-C(=W)R6(其中 W 代表氧原子或硫原子,R6 代表取代或未取代的低级烷基等)等,R3 代表-C(=Z)R19(其中 Z 代表氧原子或硫原子、R4代表取代或未取代的低级烷基等,R5代表取代或未取代的芳基等]等。